Forging a link between oncogenic signaling and immunosuppression in melanoma

Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAF(V600E) with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These re...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalili, Jahan S., Hwu, Patrick, Lizée, Gregory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601157/
https://www.ncbi.nlm.nih.gov/pubmed/23525189
http://dx.doi.org/10.4161/onci.22745
_version_ 1782475726540242944
author Khalili, Jahan S.
Hwu, Patrick
Lizée, Gregory
author_facet Khalili, Jahan S.
Hwu, Patrick
Lizée, Gregory
author_sort Khalili, Jahan S.
collection PubMed
description Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAF(V600E) with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses.
format Online
Article
Text
id pubmed-3601157
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36011572013-03-22 Forging a link between oncogenic signaling and immunosuppression in melanoma Khalili, Jahan S. Hwu, Patrick Lizée, Gregory Oncoimmunology Author's View Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAF(V600E) with vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses. Landes Bioscience 2013-02-01 /pmc/articles/PMC3601157/ /pubmed/23525189 http://dx.doi.org/10.4161/onci.22745 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Khalili, Jahan S.
Hwu, Patrick
Lizée, Gregory
Forging a link between oncogenic signaling and immunosuppression in melanoma
title Forging a link between oncogenic signaling and immunosuppression in melanoma
title_full Forging a link between oncogenic signaling and immunosuppression in melanoma
title_fullStr Forging a link between oncogenic signaling and immunosuppression in melanoma
title_full_unstemmed Forging a link between oncogenic signaling and immunosuppression in melanoma
title_short Forging a link between oncogenic signaling and immunosuppression in melanoma
title_sort forging a link between oncogenic signaling and immunosuppression in melanoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601157/
https://www.ncbi.nlm.nih.gov/pubmed/23525189
http://dx.doi.org/10.4161/onci.22745
work_keys_str_mv AT khalilijahans forgingalinkbetweenoncogenicsignalingandimmunosuppressioninmelanoma
AT hwupatrick forgingalinkbetweenoncogenicsignalingandimmunosuppressioninmelanoma
AT lizeegregory forgingalinkbetweenoncogenicsignalingandimmunosuppressioninmelanoma

Ejemplares similares